|
Aug 31
|
Genetic Technologies Full Year 2024 Earnings: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)
|
|
Jul 26
|
Genetic Technologies Strategic Restructure Driving USA Sales Growth
|
|
Jun 25
|
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
|
|
Jun 21
|
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
|
|
May 6
|
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees
|
|
Apr 30
|
Appendix 4C & Quarterly Business Update – March 2024
|
|
Apr 22
|
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
|
|
Apr 18
|
Genetic Technologies Announces $2 Million Registered Direct Offering
|
|
Apr 17
|
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
|
|
Apr 16
|
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
|
|
Apr 12
|
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
|
Apr 11
|
GTG to pilot GeneType in Breast Screen centers across the U.S.
|
|
Apr 8
|
EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
|
|
Apr 2
|
Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market
|
|
Mar 26
|
GTG Global Collaborations and Innovation Update
|
|
Mar 25
|
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
|
|
Mar 8
|
One Genetic Technologies Insider Raised Stake By 20% In Previous Year
|
|
Dec 29
|
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
|
|
Oct 30
|
Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial
|
|
Aug 9
|
Genetic Technologies Limited Announces Updated Investor Presentation
|